840 Memorial Drive
Entrance on Blackstone Street, Third Floor
About AxcellaAxcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass.
CEO: Robert Connelly
CMO: Christopher I. Wright
CFO: Thomas Leggett
Please click here for Axcella job opportunities.
83 articles with Axcella
Although some may be hopeful that the end of the COVID-19 pandemic is nearby, millions still are facing their own lifelong version of the pandemic.
Axcella Therapeutics today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022.
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
Axcella Therapeutics today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock (the “Shares”) at a purchase price of $1.91 per share.
Axcella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.
Axcella Therapeutics today announced the appointment of Robert Crane as the company’s new Chief Financial Officer.
Axcella Therapeutics today announced that patient screening is now underway in a Phase 2a trial that is investigating AXA1125, an oral product candidate, as a potential treatment for Long COVID, also known as Post COVID-19 Condition and post-acute sequelae of SARS-COV-2 infection (PASC).
Axcella Therapeutics today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical Officer and added as a member of the company’s executive team.
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference.
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
Axcella Therapeutics today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
Axcella Therapeutics today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually November 12-15, 2021.
11/1/2021Yet another busy week for clinical trial news. Here’s a look.
Axcella announced it is initiating a new clinical program to study AXA1125 in patients with Long Covid. The trial will be conducted at the Oxford Centre for Clinical Magnetic Resonance Research.
Axcella Therapeutics today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET.
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.
8/23/2021It was another busy week in clinical trial news. Here’s a look.
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
Axcella today announced the publication of results from the company’s AXA1125-003 clinical study in The American Journal of Gastroenterology
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced financial results for the second quarter ended June 30, 2021 and provided a business update.
Axcella today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET
Axcella Announces Initiation of EMMPOWER ℠ Phase 2 Clinical Trial of AXA1665